Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Heart Failure

Verquvo Approved for Heart Failure with Reduced Ejection Fraction

Brian Park, PharmD

January 27, 2021

The approval was based on data from the double-blind, placebo-controlled phase 3 VICTORIA trial.

Pediatric Cardiology

Novel Therapy Fast-Tracked for GI Dysfunction in Pediatric Patients Undergoing Heart Surgery

Brian Park, PharmD

January 20, 2021

The designation is based on positive topline data from a phase 2 study of 120 adults following open-heart surgery.

Heart Failure

Empagliflozin Under Review for Heart Failure with Reduced Ejection Fraction

Brian Park, PharmD

January 14, 2021

The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.

General Cardiology

Vaccine Candidate AZD1222 Effective Against COVID-19

Brian Park, PharmD

December 3, 2020

A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.

Stroke

Brilinta Approved to Reduce Risk for Recurrent Stroke in High-Risk Patients

Brian Park, PharmD

November 11, 2020

The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events.

Uncategorized

Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease

Brian Park, PharmD

October 29, 2020

The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.

Vascular Medicine

FDA to Review Avacopan for ANCA-Associated Vasculitis

Brian Park, PharmD

September 28, 2020

Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.

Dyslipidemia

Consistent LDL-C Lowering Reported With Twice-Yearly Inclisiran

Brian Park, PharmD

September 14, 2020

The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.

Vascular Medicine

Coronary Plaque Regression Observed With Icosapent Ethyl

Brian Park, PharmD

September 9, 2020

The phase 4 EVAPORATE study assessed the effects of icosapent ethyl on the progression of coronary atherosclerosis in 80 adult patients with elevated triglycerides.

Dyslipidemia

Evolocumab Lowers LDL-C in Pediatric Patients With HeFH

Brian Park, PharmD

September 4, 2020

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.

Next post in Dyslipidemia